The CellBio technology can simultaneously use the microfilter and fluorescent staining to separate and recover CTCs from human blood samples according to the size of cells and different surface markers. The CellBio technology at GBC has demonstrated the CTC recovery efficiency of>90 % with in-vitro samples which is better than available market techniques. The optimized structure and process design of the filter membrane are designed to separate CTCs from other blood cells while avoiding cell damage or deformation during filtration. The characterization process is developed for recognizing frequently overexpressed EPCAM and cytokeratin receptors on circulating tumor cells. During characterization, the non-nucleated interference was neglected by DAPI staining and leukocytes by CD45 recognition. The CellBio technology is not only offering high sensitivity and specificity enabling the researchers to analyze CTC but also provides an effective tool for understanding tumor progression.